HomeAI · summaries
Storia in 2 fonti
Merck, Kelun score with sac-TMT in endometrial cancer trial
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT). | Merck and Kelun-Biotech have already notched four approvals in China for their TROP2-directed ADC sacituzumab tirumotecan. Now, after meeting the primary endpoints in a phase 3 trial of certain patients with endometrial cancer, the companies are taking steps to gain clearance of sac-TMT in another indication.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
fiercepharma.com
Roche's ctDNA-guided approach in post-surgical bladder cancer pays off with Tecentriq nod
With the help of DNA testing company Natera and its personalized molecular residual disease (MRD) blood test Signatera, Roche’s PD-L1 inhibitor Tecentriq has chalked up its…
- ·
endpoints.news
Merck's ADC sac-TMT gets its first global Phase 3 win ahead of schedule
An experimental antibody-drug conjugate from Merck and Kelun-Biotech succeeded in a global Phase 3 study for the first time, giving Merck a key pipeline victory as it approaches…
- ·
Merck, Kelun score with sac-TMT in endometrial cancer trial
Over the last 18 months, Merck and Kelun-Biotech have notched four approvals in China for their TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT). |…